SCYNEXIS Inc. (SCYX)
Company Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States.
It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC).
The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).
It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp.
The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Country | United States |
| IPO Date | May 2, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Dr. David Gonzalez Angulo M.D. |
Contact Details
Address: 1 Evertrust Plaza Jersey City, New Jersey United States | |
| Website | https://www.scynexis.com |
Stock Details
| Ticker Symbol | SCYX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001178253 |
| CUSIP Number | 811292200 |
| ISIN Number | US8112922005 |
| Employer ID | 56-2181648 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Gonzalez Angulo M.D. | Chief Executive Officer, President & Director |
| Ivor Macleod CPA, M.B.A. | Chief Financial Officer |
| Scott Sukenick J.D. | Chief Legal Officer & Corporate Secretary |
| Daniella Gigante | Vice President of Human Resources & Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 27, 2025 | 4 | Filing |
| Jan 27, 2025 | 4 | Filing |
| Jan 27, 2025 | 4 | Filing |
| Jan 08, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 8-K | Current Report |
| Nov 06, 2024 | 424B5 | Filing |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |